<DOC>
	<DOCNO>NCT02460601</DOCNO>
	<brief_summary>The study aim verify efficacy safety Qizhiweitong granule Chinese patient functional dyspepsia diagnose Rome III criterion . It include two subtypes functional dyspepsia , postprandial distress syndrome abdominal pain syndrome .</brief_summary>
	<brief_title>The Efficacy Safety Qizhiweitong Granule Patients With Functional Dyspepsia Multi-center Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>1. patient write ICF sign 2. patient functional dyspepsia diagnose Rome III criterion 3. age 18y 65y ; male female . 4. patient without gastric ulcer , erosive gastritis gastric organic disease accord endoscopy past one year hospital 5. patient without hepatobiliary pancreatic disease accord Bultrasoundin past one year hospital 6. patient normal ECG ( QT interval normal range ) within one month prior enrollment center 7. patient symptom one subtype functional dyspepsia 1. history abdominal surgery ; 2. take drug relate gastrointestinal motility gastric acid secretion gastric acid drug , antiHelicobacter pylorus drug within 5 day inclusion 3. suffer hepatobiliary pancreatic disease B ultrasound 4. suffer high blood pressure uncontroled hypertension 5. diabetes mellitus 6. history thyroid disease , systemic sclerosis , systemic lupus erythematosus 7. severe mental disorder 8. pregnant woman , breastfeed woman plan become pregnant 9. allergy Qizhiweitong particle 10. symptom subtypes functional dyspepsia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>